Key result
Beta-blocker use was associated with increased mortality in patients after curative-intent surgery for pancreatic cancer (adjusted HR 1.18; 95% CI 1.04-1.34).
Why the study?
The authors sought to examine the association between beta-blocker use and survival in pancreatic cancer patients after curative-intent surgery.
Does beta-blocker use affect survival in patients undergoing curative-intent surgery for pancreatic cancer?
Cohort (n=2,592)
Yes
Does beta-blocker use affect survival in patients undergoing curative-intent surgery for pancreatic cancer?
Hazard Ratio: 1.18 (95% CI 1.04–1.34)
Beta-blocker use prior to curative-intent surgery for pancreatic cancer is associated with increased mortality, though this is likely driven by confounding by indication.
Beta-blocker use was associated with higher post-resection mortality; hypothesis-generating and should not yet change prescribing.
PURPOSE: We examined the association between use of beta-blockers and survival in pancreatic cancer patients after curative-intent surgery. METHODS: Using Danish healthcare registries, we conducted a population-based cohort study of all patients undergoing curative-intent surgery for pancreatic cancer in Denmark 1997-2021. We defined beta-blocker use according to exposure before surgery as current (≤90 days), recent (91-365 days), or former (366-730 days) use, requiring at least one filled prescription. Patients were followed from the date of surgery for up to 5 years. We used Cox regression to compute hazard ratios (HRs) of deaths with 95% confidence intervals (CIs), adjusting for age, sex, year of diagnosis, cardiovascular disease, diabetes, liver disease, alcohol, and smoking. We also conducted an active comparator analysis, where we used angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers as comparators instead of nonusers. RESULTS: We included 2592 patients, of which 16.7% were beta-blocker users. Median survival for the entire population was 24.4 months. Beta-blocker use was associated with increased mortality (adjusted HR: 1.18; 95% CI: 1.04-1.34). This was evident in current (adjusted HR: 1.19; 95% CI: 1.02-1.38) and recent (adjusted HR: 1.29; 95% CI: 1.04-1.59) but not former (adjusted HR: 0.91; 95% CI: 0.64-1.43) users. In the active comparator analysis, the association between beta-blocker exposure and mortality attenuated slightly (adjusted HR: 1.12; 95% CI: 0.93-1.35). CONCLUSIONS: We observed an association between beta-blocker use and increased mortality in patients operated for pancreatic cancer. Findings are likely explained by confounding by indication.
No takes yet. Share an insight, caveat, or question.
Kirkegård et al. (2023) conducted a cohort in Pancreatic cancer (n=2,592). Beta-blocker use vs. Nonusers was evaluated on Mortality (HR 1.18, 95% CI 1.04-1.34). Beta-blocker use was associated with increased mortality in patients after curative-intent surgery for pancreatic cancer (adjusted HR 1.18; 95% CI 1.04-1.34).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: